A Sudbury biotechnology firm, Neureka Research Corp., inked a contract with the University of Turku in Finland to develop and manufacture a patented method of detecting coronary heart disease. The four-year-old non-profit organization has exclusive rights to design and produce a prototype of a diagnostic kit for market that measures cholesterol levels. Likely clients include research agencies, pharmaceutical companies, hospitals and clinical research centres. Neureka is investing $1 million in the project that includes a federal government funding contribution. If successful, the project may be a launching pad for a manufacturing plant in Sudbury and will increase exposure for Neureka in the growing global biotechnology industry. The corporation pulls in $4 million annually in clinical research trials for 18 of the world's largest pharmaceutical companies, and organizations such as the Hospital for Sick Children of Toronto.
